how to check for prostate cancer header graphic
Prostate Problem Guide

How To Check For Prostate Cancer Using The PSA Test

One of the commonest tests for detecting the presence of prostate cancer is the prostate specific antigen, or PSA, test.

The PSA test is a simple blood test which measures the level of a specific protein produced by the prostate and indicates to your doctor whether or not there may be a problem with the prostate gland. Unusually high levels of the prostate specific antigen hormone will not in itself indicate the presence of prostate cancer, but it will show that there may be a problem with the prostate and suggest that it may be advisable to carry out further testing.

In some cases PSA testing is now included as part of routine medical examinations for men over the age of 40 and, for men with a family history of prostate cancer, may be carried out at even earlier ages. It is also becoming increasingly common for doctors to perform a digital rectal examination at the same time as the PSA test for men over the age of 50 as an additional physical check of the prostate gland.

In conducting the PSA test your doctor will take a sample of blood which is then sent to a laboratory for testing. The laboratory will then measure the level of the prostate specific antigen protein and report its findings back to your doctor.

Terms from the prostate cancer glossary:

ALPROSTADIL: a prostaglandin that relaxes the smooth muscles of the penis, enhancing blood flow, and producing erection; first produced as Caverject®, an injectable prostaglandin.

DIAGNOSIS: the evaluation of signs, symptoms and selected test results by a physician to determine the physical and biological causes of the signs and symptoms and whether a specific disease or disorder is involved.

PROTON PUMP INHIBITORS (PPI): drugs that reduce gastric acidity by inhibiting the proton pump within the gastric lining cells; examples of PPI include Prilosec® and Nexium®.

UNDETECTABLE PSA (UDPSA): defined in our research as a PSA of <0.05 using a hypersensitive assay such as DPC Immulite 3rd generation PSA or Tosoh assay.

If the results show an abnormally high level of PSA then, unless the level is especially high, your doctor may advise that this indicates a possible prostate problem which could be anything from a temporary prostate infection to an enlarged prostate or possibly prostate cancer.

At this point however, unless there are other factors which suggest that additional testing is needed, your doctor might well simply advise that the PSA test be repeated in a few months time to see whether or not your PSA levels are still elevated.

Many prostate problems are slow to develop and so repeat testing is frequently carried out over a long period of time with your doctor merely monitoring the results and charting what is sometimes referred to as the 'velocity' of your PSA. In other words, as long as your PSA levels are increasing, your doctor will monitor the speed of this increase until he feels that further testing is necessary.

There is some controversy surrounding the PSA test, not least because it does not provide a clear cut ‘yes’ or ‘no’ diagnosis for prostate cancer. Nevertheless it is an extremely valuable test for detecting early signs of problems developing within the prostate gland and is responsible for preventing many prostate cancer deaths each year.

Further information on the prostate psa test:

Local doctors weigh benefits, risks of prostate cancer screening past age 75 - Palm Beach Post


The Province

Local doctors weigh benefits, risks of prostate cancer screening past age 75
Palm Beach Post
For the 50- to 69-year-olds, "Ninety-five percent of men with PSA-detected cancer who are followed for 12 years do not die from that cancer, even in the absence of definitive treatment." PSA tests measure prostate-specific antigen, a substance in the ...
Alan Cassels: How perfectly healthy people are turned into patientsThe Province (blog)
Younger men benefit from prostate screeningCBS42

all 5 news articles »

Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society ... - MarketWatch (press release)


Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society ...
MarketWatch (press release)
"The results of this analysis, although not adequately powered for significance, support an overall survival benefit with PROVENGE across PSA quartiles," said Gerald Chodak, MD, Midwest Prostate and Urology Health Center, Weiss Memorial Hospital.

and more »